Development and validation of a real‐world model to predict 1‐year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States)
Authors' conclusion
iNPHORM is the first US-based primary prognostic study on Level 3 hypoglycaemia. Future model implementation could potentiate risk-tailored strategies that reduce real-world event occurrence and overall diabetes burden.
Study context
- Population
- Adults (18–90 years) with T1D or insulin- and/or secretagogue-treated T2D, recruited from a US nationwide probability-based internet panel; completed ≥1 follow-up questionnaireanalysed
- Participants
- 986 adults
- Outcome
- Level 3 (severe) hypoglycaemia risk
- Follow-up
- 1 year
Methodological details12-month panel survey, US-based, nationwide probability-based internet panel, Andersen and Gill's Cox survival and penalized regression with multiple imputation, Participant characteristics: T1D 17%; men 49.6%; mean age 51 (SD 14.3) years
- 12-month panel survey
- US-based
- Nationwide probability-based internet panel
- Andersen and Gill's Cox survival and penalized regression with multiple imputation
- Participant characteristics: T1D 17%; men 49.6%; mean age 51 (SD 14.3) years
Performance
As reported in the abstract
Model discrimination for 1-year Level 3 hypoglycaemia risk
Optimism corrected c-statistic
0.77
Further findings
≥1 Level 3 hypoglycaemia event(s) reported · across follow-up
- Proportion with ≥1 Level 3 event(s)
- 035.1% (95% CI 32.2-38.1)
Level 3 hypoglycaemia event rate · across follow-up
- Events per person-year
- 5.0 (95% CI 4.1-6.0)
Original publication
Development and validation of a real‐world model to predict 1‐year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States). Diabetes Obes Metab. Published 6 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →